Post by SOPHiA GENETICS

Building on our announcement of the executive leadership succession, we are excited to share a financial overview that sets the stage for this next chapter. "2025 was a tremendous year for SOPHiA GENETICS as we reaccelerated revenue growth and materially exceeded our new business bookings target, setting the stage for robust future growth," said Dr. Jurgi Camblong, Co-founder and CEO at SOPHiA GENETICS. "Our strong performance in 2025 positions us well for continued growth in 2026 and beyond. Growth catalysts for the year ahead include our best-in-class Liquid Biopsy application MSK-ACCESS® powered with SOPHiA DDM™, valuable opportunities in the U.S. market, and a reinvigorated BioPharma business. We look forward to continuing to demonstrate operating leverage in 2026 and have high confidence in a material improvement in our financial position." 2025 Preliminary Unaudited Financial Highlights: · Q4 Momentum: Revenue growth of approximately 20% year-over-year. · Full Year Strength: Revenue growth of approximately 18% year-over-year. We are initiating full-year 2026 revenue guidance between $92 million and $94 million, representing an acceleration to approximately 20% to 22% growth. Our team is on the ground at #JPM2026 in San Francisco this week! 👋 If you are there, connect with Ross Muken, George Cardoza, Kellen Sanger, and Jess Lambe to discuss how we are democratizing data-driven medicine.